Uveal melanoma is a type of cancer that develops in the middle layer of your eye called the uvea. It can cause symptoms like blurry vision, floaters, or loss of vision. Melanoma is a type of ...

The following is a summary of “Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

Designation will ease the gene-based breakthrough’s transition from laboratory to clinic with tax breaks and other investment ...

Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company ...

The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

You don’t have to have a student at East Elementary to know the name Brian DeMarco. The fourth-grade teacher has contributed ...